bexagliflozin · Theracosbio · NDA 214373
Brenzavvy
Earliest generic entry, as listed
5 Oct 2041
Blocked by patent: US 12594243.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12594243 | product | 5 Oct 2041 |
| US 8987323 | substance, product | 14 May 2032 |
| US 10533032 | use U-2214 | 3 Jul 2031 |
| US 10981942 | substance, product | 13 Jun 2031 |
| US 7838499 | substance, product, use U-2214 | 30 Jan 2029 |
| US 8106021 | use U-2214 | 22 Aug 2028 |
| US 8802637 | substance, product, use U-2214 | 22 Aug 2028 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 20 Jan 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214373 · 001 · RLD | tablet, oral | 20MG | 5 Oct 2041 |